Insider filing · ERNA

Charles Cherington bought $2.0M of Ernexa Therapeutics (ERNA)

Executed Feb 10, disclosed Feb 18, 7 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Feb 17), the stock returned -23.7% (delay-adjusted); from the execution session (Feb 10), -9.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

CC Charles Cherington 10% owner profile →

Charles Cherington (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ERNA. Across 1 priced purchase filing, the average 21-session return was -9.4% from execution and -23.7% from disclosure (delay-adjusted; derived). The largest single filing was $2.0M of ERNA (4,000,000 sh × $0.50, as filed), executed Feb 10.

ERNA ERNA ERNA · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→